NOV 002 is now Waiting for FDA Approval.
__________________________________________
Novelos Therapeutics Obtains FDA Fast Track Designation for NOV-002 Lung Cancer Treatment
Monday August 7, 8:30 am ET
NEWTON, Mass.--(BUSINESS WIRE)--Aug. 7, 2006--Novelos Therapeutics, Inc. (OTCBB: NVLT - News), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the Food and Drug Administration (FDA) has granted Fast Track designation to NOV-002 for use in combination with first-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). The FDA's Fast Track program is designed to facilitate the development and accelerate the review process for new drugs that have the potential to address a serious and unmet medical need for conditions such as advanced NSCLC.
2007-01-07
08:27:59
·
2 answers
·
asked by
Bixbyte
4